Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:30:02 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Z:BMY - BRISTOL-MYERS SQUIBB CO - http://www.bristolmyers.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMY - Z0.344.69·44.752.444.7060.72,522309    69.74  47.5809:12:4406:5915 min RT 2¢

Recent Trades - Last 10 of 309
Time ETExPriceChangeVolume
09:12:44Z44.70 50
09:12:40Z44.720.023
09:12:40Z44.720.022
09:12:40Z44.720.023
09:12:40Z44.720.0250
09:12:40Z44.720.0238
09:12:40Z44.720.0234
09:12:39Z44.720.023
09:12:39Z44.720.023
09:12:37Z44.720.0238

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-26 06:59U:BMYNews ReleaseCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(TM) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2024-04-25 06:59U:BMYNews ReleaseBristol Myers Squibb Reports First Quarter Financial Results for 2024
2024-04-22 06:59U:BMYNews ReleaseBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
2024-04-11 09:11U:BMYNews ReleaseBuilding a Better Future: Bristol Myers Squibb 2023 ESG Report
2024-04-08 11:30U:BMYNews ReleaseKRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
2024-04-08 07:03U:BMYNews ReleaseBristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
2024-04-06 13:15U:BMYNews ReleaseBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
2024-04-06 13:15U:BMYNews ReleaseBristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
2024-04-05 09:05U:BMYNews ReleaseU.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
2024-04-02 20:08U:BMYNews ReleaseEuropean Commission Expands Approval of Bristol Myers Squibb's Reblozyl(TM) (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
2024-04-02 14:32U:BMYNews ReleaseBristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
2024-03-29 09:46U:BMYNews ReleaseBristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes